Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Inclusion Criteria: 1. Male or female patients ≥18 years of age; 2. CML-CP patients diagnosed with CML within half a year；Patients who have been using second-generation TKI nilotinib or flumatinib for first-line treatment in clinical practice, but the history of continuous treatment does not exceed 3 months；3.patients are allowed to receive hydroxyurea treatment before first-line treatment with nilotinib or flumartinib; patients treated with interferon for no more than 3 months and other TKIs for no more than 2 weeks; 4.Patients who must sign informed consent before screening Exclusion Criteria: 1. T315I mutation ; Y253F/H, E255K/V, F359C/V/I mutations in the nilotinib group; 2. Entry into another therapeutic clinical trial; 3. Concomitant diseases that, according to the investigator's judgment, pose a serious risk to the patient's safety or completion of the study; 4. History of neurological or psychiatric disorders, including epilepsy or dementia; 5. Major surgery within 4 weeks prior to Day 1 of study; 6. Patients with another primary malignancy,unless the other primary malignancy is currently stable or does not need active intervention; 7. Women of reproductive age or men who are unable to use adequate methods of contraception, including women who are pregnant or breastfeeding; 8. ECOG≥3; 9. Patients who are unable to compliance with study or follow-up procedures;